As mentioned, gefitinib, erlotinib, lapatinib, dacomitinib, and osimertinib are EGFR inhibitors received approval for non–small cell lung cancer (NSCLC) treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.